The AIDS Clinical Trials Unit at Case Western Reserve University (CWRU) is applying for continuation of funding for participation in the AIDS Clinical Trials Group, Robert Schooley, project leader. Since its inception in 1987, the CWRU ACTU has established and maintained an outstanding reputation for the performance of AIDS treatment trials. Within a 60 minute drive of a 19 county region of 5 million persons that has reported 40% of all Ohio AIDS patients, the CWRU ACTU is located at University Hospitals and MetroHealth Medical Center in Cleveland. The qualifications of the CWRU ACTU include: 1. Experienced physician/investigator, nursing and data management staff. 2. Superb facilities for conduct of treatment trials research including dedicated space for AIDS treatment/trials, NIH funded General Clinical Research Center, DAIDS Certified Virology and flow cytometry facilities, ACTG-supported Immune Function Laboratory. 3. Outstanding record of accrual and retention of patients into ACTG trials including underserved minorities and women. 4. Significant contributions to a pathogenesis-oriented ACTG scientific agenda, particularly in disciplines of virology, immune-based therapies and mycobacterial disease. 5. Consistent high level performance of ACTG trials; this unit has been recognized by DAIDS as one of the top eight units in the ACTG in terms of clinical trials performance 6. Well organized, comprehensive outreach/community participation activities that have provided the ACTU an excellent reputation in Northern Ohio.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025879-10
Application #
2003448
Study Section
Special Emphasis Panel (SRC (56))
Project Start
1987-09-30
Project End
1999-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Chang, J Judy; Woods, Matt; Lindsay, Robert J et al. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 208:830-8
Kyeyune, Fred; Nankya, Immaculate; Metha, Samar et al. (2013) Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS 27:1899-909
Imamichi, Hiromi; Degray, Gerald; Asmuth, David M et al. (2011) HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25:159-64
Anthony, D D; Umbleja, T; Aberg, J A et al. (2011) Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 29:3558-63
Tebit, Denis M; Lobritz, Michael; Lalonde, Matthew et al. (2010) Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol 84:9817-30
Lok, Judith J; Bosch, Ronald J; Benson, Constance A et al. (2010) Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 24:1867-76
Kalayjian, Robert C (2010) The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 17:59-71
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Lassen, Kara G; Lobritz, Michael A; Bailey, Justin R et al. (2009) Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 5:e1000377
Robbins, Gregory K; Spritzler, John G; Chan, Ellen S et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48:350-61

Showing the most recent 10 out of 116 publications